Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saruparib in Platinum-Sensitive, HRDsig+ Solid Tumors
NCT07832630Phase 2Not yet recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Nov 2026
- Primary completion
- Nov 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of saruparib in solid tumor, sponsored by Abramson Cancer Center. Primary endpoint: Objective Response Rate up to 2 years. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
saruparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07832630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07832630.